We are producing and shipping all dose strengths of Wegovy^®, running our manufacturing lines 24 hours a day, seven days a week, manufacturing more Wegovy® than ever before.

Since May of 2023, we have been thoughtfully and responsibly managing shipments of the three lowest dose strengths of Wegovy^® in an effort to support continuity of care for existing patients while we worked to increase our production capacity.  

In January of 2024, we made a commitment to double the amount of the lower dose strengths available in the U.S. market and gradually increase overall supply throughout the year. 

As a result of our efforts, we have served over one million U.S. patients with Wegovy^® and total weekly prescriptions have more than doubled compared to the beginning of the year.

Based on this progress, Novo Nordisk continues to supply all Wegovy^® dose strengths to the U.S. market. 

Four of the five dose strengths (0.5 mg, 1 mg, 1.7 mg and 2.4 mg) are now available but we will continue to manage shipments of the 0.25 mg starting dose of Wegovy^®, to responsibly initiate patients on treatment consistent with our commitment to patients and focus on continuity of care.    

Increasing our manufacturing capacity is a key factor in our ability to produce more medicines and we’re investing heavily to ensure that we’re growing to meet demand and continuing to run our facilities 24 hours a day, 7 days a week.

We will do our best to support those who want to start taking Wegovy^® but it is important to recognize that overall demand will continue to exceed supply. This means that some patients may still have difficulty filling their prescriptions. We will continue to closely monitor market dynamics and prescribing trends.

We understand how frustrating this is for the communities we serve and recognize how important it is for people currently using Wegovy^® to continue their weight management journey. We recommend that those who experience challenges filling their prescriptions speak with a healthcare professional about the best approach to their treatment, so this does not halt their pursuit of obesity care.

We primarily distribute our products to wholesalers, which then supply retail pharmacies nationwide. Which specific pharmacies or retailers get Wegovy^® is determined by several factors outside of Novo Nordisk control, including wholesaler distribution and order fulfilment practice.

If you are unable to fill your Wegovy^® prescription, you should speak with your healthcare professional about your treatment plan to determine the best course of action and options available. Healthcare professionals know your past and current medical history and are best equipped to make clinical recommendations.

We also recommend that healthcare providers take into consideration the limited supply of Wegovy^® as part of their decision-making when initiating new patients on therapy, recognizing the possibility of disruption in care.

Although Wegovy^® and Ozempic^® both contain semaglutide, they are different products with different indications, dosages, prescribing information, and titration schedules, as approved by the FDA. Each medication has a unique safety and efficacy profile which is detailed in its respective product label. The products are not interchangeable. We support our medicines being prescribed to patients who meet the indicated criteria and only promote the FDA-approved indications of our medicines for appropriate patients. Click here to read more about our commitment to the responsible use of our medicines.

At this time, we do not recommend switching to Saxenda^® as a viable alternate treatment, as we cannot guarantee supply to match the continuous rising demand for weight management medications.

We are aware that there are companies claiming to have availability of Wegovy^® or semaglutide. We want consumers and healthcare professionals to know and be very clear that Novo Nordisk does not sell Wegovy^®, or its active ingredient, semaglutide, for the purposes of compounding with other products. Novo Nordisk has not conducted studies to evaluate the safety and efficacy of Wegovy^® when compounded with other ingredients. Novo Nordisk is the only company that has FDA approval to market Wegovy^®, and we supply it in a disposable single-use pen available by prescription only. In addition, the FDA shared safety information on compounded semaglutide on their website. For more information, click here: Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss | FDA.

We are aware that several compounding pharmacies, weight-loss clinics, and medical spas are claiming to sell or offer compounded semaglutide products. Novo Nordisk is actively monitoring and taking action against entities that are engaging in the unlawful sale of compounded semaglutide, disseminating false advertising, and infringing its trademarks. Novo Nordisk is the only company in the U.S. with FDA-approved products containing semaglutide, identified under the trade names Wegovy^®, Ozempic^®, and Rybelsus^®. No FDA-approved generic versions of semaglutide currently exist. Compounded products do not have the same safety, quality, and effectiveness assurances as our FDA-approved drugs, and may expose patients to health risks.

Novo Nordisk cannot validate the safety or effectiveness of products claiming to contain semaglutide that are not one of our own branded products. We are actively working to ensure broad public awareness regarding the difference between our FDA-approved products and other medicines being labeled as “semaglutide” and sold by such entities. Further, the practice of selling compounded semaglutide medicines under Novo Nordisk trade names has the potential to create consumer confusion and deception, and we will not tolerate the unauthorized and inappropriate usage of our brand trademarks by third parties.

Novo Nordisk is not supplying any telehealth companies with Wegovy^®. Any healthcare professionals prescribing Wegovy^® through telehealth companies will face the same supply challenges as all other healthcare professionals and patients across the U.S.

We see the growing trend of weight-management telehealth providers and have heard media reports that some telehealth providers are not providing sufficient clinical evaluations prior to prescribing semaglutide containing medicines, including Wegovy^® and Ozempic^®. Novo Nordisk medicines should only be prescribed after a close consultation between a licensed healthcare provider and a patient – considering the medication’s benefits and risks for that individual patient – and should only be taken under the supervision of a licensed healthcare professional.